What is a Self-Spreading Vaccine, and what does it have to do with the COVID-19 vaccine?

BY SIMONE J. SMTH

People have been excited to get the new vaccine and for good reason. We have been told on the news how great it is. There seems to be a lot of trust in doctors and scientists who are still researching how this is going to affect people in the future.

Well, I have new updates for you, not so new for some people.

In 2018, John Hopkins Bloomberg School of Public Health’s Centre for Health Security discussed in their report the idea of using a type of vaccine that intentionally spread to others for protection against disease.

Under the section, “Self-Spreading Vaccines,” (page 45) the Johns Hopkins document states,

“Self spreading vaccines are genetically engineered to move through populations like communicable diseases, but rather than causing disease, they confer protection. The vision is that a small number of individuals in a target population could be vaccinated, and the vaccine strain would then circulate in the population much like a pathogenic virus, resulting in rapid, widespread immunity.”

“Isn’t this unethical,” you ask? The paper admits self-spreading vaccines being implemented would come with challenges, such as “informed consent” and potentially life-threatening contraindications.

“The ethical and regulatory challenges surrounding informed consent and prevention and monitoring of adverse events would be critical challenges to implementing this approach even in an extreme event,” the document states.

Hmmmm! Let’s move on.

There was another document that went viral last week. It was Pfizer’s report that introduced the idea of occupational exposure. You may have heard this referred to as vaccine shedding, but after I read it, it sounded a lot like a vaccine that was spreadable, very similar to what was presented in the John Hopkins document

Section: 8.3.5.3. Occupational Exposure
“An occupational exposure occurs when a person receives unplanned direct contact with a vaccine test subject, which may or may not lead to the occurrence of an adverse event,” the Pfizer document warns.

“These people may include health care providers, family members, and other people who are around the trial participant.

The investigator must report occupational exposure to Pfizer Safety within twenty-four hours of the investigator’s awareness, regardless of whether there is an associated SAE.

The information must be reported using the Vaccines SAE Report Form. Since the information does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed Vaccines SAE Report Form is maintained in the investigator site file.”

The Centre for Disease Control’s COVID-19 Clinical Team has refuted these documents. “There is no way for a COVID-19 vaccinated person to shed the vaccine,” they reportedly emailed to Reuters after being questioned about the document.

Dr Christopher Zahn, Vice President for Practice Activities at the American College of Obstetricians and Gynaecologists, had this “This is a conspiracy that has been created to weaken trust in a series of vaccines that have been demonstrated in clinical trials to be safe and effective.”

I leave this for you to go through if you are interested. I swear community; I am not making any of this up.

Below are the documents that are being found online. I find it interesting that they would release this information with such transparency. Take a look, and see how the information sits with you. Stay researching.

Johns Hopkins Bloomberg School of Public Health’s Centre for Health Security
Technologies to Address Global Catastrophic Biological Risks
https://jhsphcenterforhealthsecurity.s3.amazonaws.com/181009-gcbr-tech-report.pdf

Pfizer Document
A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
https://media.tghn.org/medialibrary/2020/11/C4591001_Clinical_Protocol_Nov2020_Pfizer_BioNTech.pdf